Mirum Pharmaceuticals reported a second-quarter 2026 loss of 80 cents per share, wider than the Zacks Consensus Estimate of a loss of 77 cents, while revenues of $176.2 million beat the $165 million consensus and grew 37.9% year over year. The company raised its full-year 2026 worldwide net product sales guidance to $680–$700 million from the prior $660–$680 million, driven by strong demand for Livmarli and bile acid products. Livmarli net product sales reached $128.7 million, up 46%, with $92 million in the United States and $37 million in ex-U.S. markets, and the FDA approved a new tablet formulation of Livmarli for the treatment of cholestatic pruritus in patients with Alagille syndrome and progressive familial intrahepatic cholestasis, launched in June 2025. Bile acid product sales, comprising Cholbam and Ctexli, rose 20% to $47.5 million. Mirum also provided pipeline updates, including completed enrollment in the phase III EXPAND study for Livmarli, expected top-line data from volixibat studies, and a Priority Review for zilurgisertib in fibrodysplasia ossificans progressiva with a target action date of September 26, 2026.
Mirum Pharmaceuticals IncQ2 revenue beat and raised 2026 guidance
Incyte Corporation
Liquidia Technologies Inc
Repligen Corporation